A Retrospective Quality Improvement Study of Pharmacist-Directed Vancomycin Dosing Among Adult Home Infusion Patients
Infusion Journal · 2024
DOI: 10.70776/staj7991 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infusion Journal, 2024. Verfasst von Claire Meredith und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Vancomycin is widely used to treat gram-positive infections. Vancomycin therapy is accompanied by the clinical monitoring of trough levels in order to maintain therapeutic efficacy and patient safety. The home infusion patients receiving vancomycin therapy may undergo physiologic changes from inpatient care to home infusion that could affect their response to therapy. Home infusion pharmacists are uniquely positioned to facilitate continued acute monitoring, assess pharmacokinetic changes, and further support the patient transitioning to the post-acute care setting. There is insufficient data regarding the impact of pharmacist-directed vancomycin dosing and utilizing a standardized protocol within the home infusion setting. Using results from this study, this institution intends to demonstrate the value that pharmacists have in recommending therapeutic adjustments, developing a formal pharmacist-directed dosing protocol, and providing education to clinical pharmacists about the use of that protocol.
Methods
This retrospective, quality improvement study characterized data from patients receiving pharmacist directed vancomycin dosing. This study included patients ≥18 years of age who received vancomycin dosed to a goal trough of 15-20 mg/L and were on service between January 1, 2021, and December 31, 2021. The primary objective of this study was to evaluate the efficacy of pharmacist-directed vancomycin therapy in a home infusion setting by analyzing rates of therapeutic trough levels, duration of therapy, and resolution of infection. The secondary objective of this study was to evaluate safety outcomes in patients receiving vancomycin in a home infusion setting by analyzing the incidence of acute kidney injury (AKI).
Results
Thirty-one patients met the inclusion criteria for retrospective analysis. Eighteen patients (58.06%) experienced resolution of infection. Of the patients who did not meet the criteria for resolution of infection, 11 (78.6%) had therapeutic extensions. The median duration for therapeutic extensions was 12 days. The average trough with pharmacist-directed dosing was 16.71 ± 4.84 mg/mL. When assessing the secondary outcomes of patients with supratherapeutic troughs, it was reported that 4 patients (13%) experienced adverse safety events. Two patients (6.5%) experienced AKI secondary to vancomycin therapy. Both patients had supratherapeutic vancomycin troughs at the time of AKI appearance.
Conclusion
Pharmacist-directed dosing led to sustained improvements in therapeutic troughs and maintained a low incidence of AKI. Keywords: Vancomycin, pharmacokinetic dosing, clinical monitoring, antibiotic, infectious disease, home infusion
Zitieren
APA
Meredith, C., Frey, L., George, S., & Zielke, M. (2024). A Retrospective Quality Improvement Study of Pharmacist-Directed Vancomycin Dosing Among Adult Home Infusion Patients. Infusion Journal. https://doi.org/10.70776/staj7991
Vancouver
Meredith C, Frey L, George S, Zielke M. A Retrospective Quality Improvement Study of Pharmacist-Directed Vancomycin Dosing Among Adult Home Infusion Patients. Infusion Journal. 2024. doi:10.70776/staj7991
BibTeX
@article{Meredith2024,
author = {Meredith, Claire and Frey, Leita and George, Shelby and Zielke, Megan},
title = {A Retrospective Quality Improvement Study of Pharmacist-Directed Vancomycin Dosing Among Adult Home Infusion Patients},
journal = {Infusion Journal},
year = {2024},
doi = {10.70776/staj7991}
}
EUVIMED